The cost of premature cancer-related mortality: A review and assessment of the evidence

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 14, Issue 3, 2014, Pages 355-377

  Hanly, Paul ^a   Pearce, Alison ^b   Sharp, Linda ^b  

^a NATIONAL COLLEGE OF IRELAND   (Ireland)

^b NATIONAL CANCER REGISTRY IRELAND   (Ireland)

Author keywords

cancer; economic burden; premature mortality; productivity costs; societal

Indexed keywords

CANCER MORTALITY; CAPITAL; COST BENEFIT ANALYSIS; EMPLOYMENT; EUROPE; HEALTH CARE COST; HEALTH CARE DISPARITY; HOUSEHOLD; HUMAN; KOREA; MALIGNANT NEOPLASTIC DISEASE; PREMATURE MORTALITY; PUERTO RICO; REVIEW; SALARY; SOCIAL STATUS; TREND STUDY; UNEMPLOYMENT; UNITED STATES; COST; COST OF ILLNESS; ECONOMICS; MORTALITY; NEOPLASM; PRODUCTIVITY;

COST OF ILLNESS; COSTS AND COST ANALYSIS; EFFICIENCY; EUROPE; HEALTH CARE COSTS; HUMANS; NEOPLASMS;

EID: 84900793710     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.2014.909287     Document Type: Review

References (71)

1. International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. 2014. Available from: http://globocan.iarc.fr/Pages/online.aspx
2. Soerjomataram I, Lortet-Tieulent J, Parkin DM, et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet 2012;380(9856):1840-50
3. Rice DP. Cost of illness studies: what is good about them? Inj Prev 2000;6: 177-9
4. Jonsson B. Ten arguments for a societal perspective in the economic evaluation of medical innovations. Eur J Health Econ 2009; 10(4):357-9
5. Lidgren M, Wilking N, Jönsson B. Cost of breast cancer in Sweden in 2002. Eur J Health Econ 2007;8(1):5-15
6. Broekx S, Hond ED, Torfs R, et al. The costs of breast cancer prior to and following diagnosis. Eur J Health Econ 2011;12(4): 311-17
7. Tingstedt B, Andersson E, Flink A, et al. Pancreatic cancer, healthcare cost, and loss of productivity: a register-based approach. World J Surg 2011;35(10): 2298-305
8. Drummond M, Sculpher M, Torrance G, et al. Methods for the economic evaluation of healthcare programmes. 3rd edition. Oxford University Press; New York: 2005
9. Tarricone R. Cost-of-illness analysis. What room in health economics? Health Policy 2006;77(1):51-63
10. Zhang W, Bansback N, Anis AH. Measuring and valuing productivity loss due to poor health: a critical review. Soc Sci Med 2011;72(2):185-92
11. Hanly P, Timmons A, Walsh PM, Sharp L. Breast and prostate cancer productivity costs: a comparison of the human capital approach and the friction cost approach. Value Health 2012;15(3):429-36
12. Hanly P, Walsh PM, O Ceilleachair A, et al. Work-related productivity losses in an era of ageing populations: the case of colorectal cancer. J Occup Environ Med 2013;55(2):128-34
13. Tranmer JE, Guerriere DN, Ungar WJ, Coyte PC. Valuing patient and caregiver time: a review of the literature. Pharmacoeconomics 2005;23(5):449-59
14. Krol M, Brouwer W, Rutten F. Productivity costs in economic evaluations: past, present, future. Pharmacoeconomics 2013;31(7): 537-49
15. Rice DP. Estimating the cost of illness. Health Economics Series, no 6. DHEW pub no (PHS); Washington, DC: 1966. p. 947-6
16. Rice DP. Estimating the cost of illness. Am J Public Health Nations Health 1967;57(3): 424-40
17. Rice DP. Cost of illness studies: what is good about them? Inj Prev 2000;6(3):177-9
18. Mushkin SJ. Health as an investment. Investment in human beings. J Political Econ 70(5) part 1962;2:129-57
19. Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics 1998;13(1 Pt 1):1-7
20. Krol M, Brouwer WB, Severens JL, et al. Productivity cost calculations in health economic evaluations: correcting for compensation mechanisms and multiplier effects. Soc Sci Med 2012;75(11):1981-8
21. Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ 1995;14(2): 171-89
22. Oliva J, Lobo F, Lopez-Bastida J, et al. Indirect costs of cervical and breast cancers in Spain. Eur J Health Econ 2005;6(4): 309-13
23. Nicholson S, Pauly MV, Polsky D, et al. Measuring the effects of work loss on productivity with team production. Health Econ 2006;15(2):111-23
24. Zhang W, Bansback N, Anis AH. Measuring and valuing productivity loss due to poor health: a critical review. Soc Sci Med 2011;72(2):185-92
25. Gold M, Siegel J, Russell L, Weinstein M. Cost-effectiveness in health and medicine. Oxford University Press; Oxford: 1996
26. Tilling C, Krol M, Tsuchiya A, et al. In or out? Income losses in health state valuations: a review. Value Health 2010;13(2):298-305
27. Olsen JA, Smith RD. Theory versus practice: a review of 'willingness-to-pay' in health and health care. Health Econ 2001; 10(1):39-52
28. Knies S, Severens JL, Ament AJ, Evers SM. The transferability of valuing lost productivity across jurisdictions. Differences between national pharmacoeconomic guidelines. Value Health 2010;13(5): 519-27
29. Li C, Ekwueme DU, Rim SH, Tangka FK. Years of potential life lost and productivity losses from male urogenital cancer deaths- United States, 2004. Urology 2010;76(3): 528-35
30. Blomqvist P, Lycke J, Strang P, et al. Brain tumours in Sweden 1996: care and costs. J Neurol Neurosurg Psychiatry 2000;69(6): 792-8
31. Nilsson GH, Carlsson L, Dal H, Ullen H. Skin diseases caused by ultraviolet radiation: the cost of illness. Int J Technol Assess Health Care 2003;19(4):724-30
32. Reis A, Ihle P, Paulus U, et al. Cost of illness of malignant lymphoma in Germany. Eur J Cancer Care (Engl) 2006;15(4): 379-85
33. Tinghög G, Carlsson P, Synnerstad I, Rosdahl I. Societal cost of skin cancer in Sweden in 2005. Acta Derm Venereol 2008;88(5):467-73
34. Morris S, Cox B, Bosanquet N. Cost of skin cancer in England. Eur J Health Econ 2009;10(3):267-73
35. Ivanauskiene R, Padaiga Z, Vanagas G, Juozaityte E. Indirect costs of breast cancer in Lithuania in 2008. Pol Ann Med 2010; 17(1):25-35
36. Purmonen T, Nuttunen P, Vuorinen R, et al. Current and predicted cost of metastatic renal cell carcinoma in Finland. Acta Oncol 2010;49(6):837-43
37. Konnopka A, Bodemann M, Konig HH. Health burden and costs of obesity and overweight in Germany. Eur J Health Econ 2011;12(4):345-52
38. Macioch T, Hermanowski T. The indirect costs of cancer-related absenteeism in the workplace in Poland. J Occup Environ Med 2011;53(12):1472-7
39. Oliva-Moreno J. Loss of labour productivity caused by disease and health problems: what is the magnitude of its effect on Spain's economy? Eur J Health Econ 2012;13(5): 605-14
40. Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol 2013;14(12):1165-74
41. Max W, Rice DP, Sung HY, et al. The economic burden of prostate cancer, California, 1998. Cancer 2002;94(11): 2906-13
42. Max W, Rice DP, Sung HY, et al. The economic burden of gynecologic cancers in California, 1998. Gynecol Oncol 2003; 88(2):96-103
43. Insinga RP. Annual productivity costs due to cervical cancer mortality in the United States. Womens Health Issues 2006;16(5): 236-42
44. Bradley CJ, Yabroff KR, Dahman B, et al. Productivity costs of cancer mortality in the United States: 2000-2020. J Natl Cancer Inst 2008;100(24):1763-70
45. Ekwueme DU, Chesson HW, Zhang KB, Balamurugan A. Years of potential life lost and productivity costs because of cancer mortality and for specific cancer sites where human papillomavirus may be a risk factor for carcinogenesis-United States, 2003. Cancer 2008;113(10 Suppl):2936-45
46. Yabroff KR, Bradley CJ, Mariotto AB, et al. Estimates and projections of value of life lost from cancer deaths in the United States. J Natl Cancer Inst 2008;100(24):1755-62
47. Max W, Sung HY, Stark B. The economic burden of breast cancer in California. Breast Cancer Res Treat 2009;116(1):201-7
48. Ekwueme DU, Guy GP Jr, Li C, et al. The health burden and economic costs of cutaneous melanoma mortality by race/ethnicity-United States, 2000 to 2006. J Am Acad Dermatol 2011;65(5 Suppl 1): S133-43
49. Bradley CJ, Lansdorp-Vogelaar I, Yabroff KR, et al. Productivity savings from colorectal cancer prevention and control strategies. Am J Prev Med 2011;41(2): e5-e14
50. Sorensen SV, Goh JW, Pan F, et al. Incidence-based cost-of-illness model for metastatic breast cancer in the United States. Int J Technol Assess Health Care 2012;28(1):12-21
51. Kim SG, Hahm MI, Choi KS, et al. The economic burden of cancer in Korea in 2002. Eur J Cancer Care (Engl) 2008;17(2): 136-44
52. Ortiz-Ortiz KJ, Perez-Irizarry J, Marin-Centeno H, et al. Productivity loss in Puerto Rico's labor market due to cancer mortality. PR Health Sci J 2010;29(3): 241-9
53. Kang JH, Jeong BG, Cho YG, et al. Socioeconomic costs of overweight and obesity in Korean adults. J Korean Med Sci 2011;26(12):1533-40
54. OECD. StatExtracts. PPPs and exchange rates. 2014. Available from: http://stats.oecd. org/Index. aspx?DataSetCode=SNA-Table4
55. Cooper BS, Rice DP. The economic cost of illness revisited. Soc Secur Bull 1976;39: 21-36
56. Krol M, Brouwer WB. How to estimate productivity costs in economic evaluations. Pharmacoeconomics 2014;32(4):335-44
57. Koopmanschap MA, Rutten FF. Indirect costs: the consequences of production loss or increased costs of production. Med Care 1996;34(12):DS59-68
58. OECD. Pensions at a glance 2013: retirement-income systems in OECD and G20 countries. 2014 (January/15)
59. Anttila A, von Karsa L, Aasmaa A, et al. Cervical cancer screening policies and coverage in Europe. Eur J Cancer 2009; 45(15):2649-58
60. Zavoral M, Suchanek S, Zavada F, et al. Colorectal cancer screening in Europe. World J Gastroenterol 2009;47:5907-15
61. OECD. Employment policies and data. Key employment statistics. 2014. Available from: http://www.oecd.org/els/emp/keyemploymentstatistics.htm#lm
62. Cancer Research UK Cancer incidence by age. 2014. Available from: http://www.cancerresearchuk.org/cancer-info/cancerstats/incidence/age/
63. World Cancer Research Fund International. Data comparing more and less developed countries. 2014. Available from: http://www.wcrf.org/cancer- statistics/developed-countries-cancer-statistics.php
64. Commission of the European Communities. Communication from the commission to the European parliament, the council, the European economic and social committe and the committee of the regions on action against cancer: European partnership. COM 2009;291/4: 1-10
65. Krol M, Papenburg J, Koopmanschap M, Brouwer W. Do productivity costs matter?: the impact of including productivity costs on the incremental costs of interventions targeted at depressive disorders. Pharmacoeconomics 2011;29(7):601-19
66. Williams A. Cost-effectiveness analysis: is it ethical? J Med Ethics 1992;18:7-11
67. Carter AJ, Nguyen CN. A comparison of cancer burden and research spending reveals discrepancies in the distribution of research funding. BMC Public Health 2012;12:526
68. Burnet NG, Jefferies SJ, Benson RJ, et al. Years of life lost (YLL) from cancer is an important measure of population burden- and should be considered when allocating research funds. Br J Cancer 2005;92:241-5
69. Branton PE. Does Canadian research investment relate to cancer burden? Lancet Oncol 2008;9:82-3
70. Dear RF, Barratt AL, McGeechan K, et al. Landscape of cancer clinical trials in Australia: using trial registries to guide future research. Med J Aust 2011;194: 387-91
71. Stephens JM, Handke B, Doshi JA; On behalf of the HTA Principles Working Group, part of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) HTA Special Interest Group (SIG). International survey of methods used in health technology assessment (HTA): does practice meet the principles proposed for good research. Compar Eff 2012;2012:29-44